ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
PetIQ, Inc. (PETQ) stock declined over -0.03%, trading at $30.98 on NASDAQ, down from the previous close of $30.99. The stock opened at $30.99, fluctuating between $30.98 and $31.00 in the recent session.
PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at 2,900 community clinics and wellness centers hosted at pet retailers across 42 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
Employees | 1121 |
Beta | 1.74 |
Sales or Revenue | $1.10B |
5Y Sales Change% | 0.232% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep